ReviewBiomedicines2021
Trifarotene: A Current Review and Perspectives in Dermatology.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Topical, light-based, and complementary interventions for acne: an overview of systematic reviews.The Cochrane database of systematic reviews · 2024Pooled it
- Topical retinoids: Novel derivatives, nano lipid-based carriers, and combinations to improve chemical instability and skin irritation.Journal of cosmetic dermatology · 2024Pooled it
- Effect of Chinese herbal medicine injections for treatment of psoriasis vulgaris: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Retinoids in cancer chemoprevention and therapy: Meta-analysis of randomized controlled trials.Frontiers in genetics · 2022Pooled it
- Treatment of flat warts with trifarotene.Dermatology reports · 2026Article
- Successful Trifarotene Treatment of a Typical Kyrle's Disease With Overview of Topical Therapies.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026Article
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- Divergent System Organ Class Safety Profiles of Isotretinoin Versus Topical Retinoids: An EudraVigilance Disproportionality Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Targeting macrophage polarization: mechanisms and potential of mesenchymal stromal/stem cells therapy in acne treatment- a narrative review.Frontiers in immunology · 2026Review
- Review
- Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions.European journal of medical research · 2025Review
- Local Chemotherapy of Skin Pre-Neoplastic Lesions and Malignancies from the Perspective of Current Pharmaceutics.Pharmaceutics · 2025Review
- A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board.Dermatology and therapy · 2025Article
- Retinoids as Alternative Antifungal Agents AgainstMicroorganisms · 2025Article
- Review
- Metformin Therapy for Acne Vulgaris: A Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.International journal of molecular sciences · 2024Review
- A Comprehensive Review of the Acne Grading Scale in 2023.Annals of dermatology · 2024Review
- All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia.Frontiers in pharmacology · 2024Review
- Retinoid Therapy in a Case of Harlequin Ichthyosis with a Short Literature Review.Case reports in dermatological medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth-generation retinoid with a selective action on RAR-γ. In this review, we reported the trials-both concluded and in progress-including the use of trifarotene in dermatological diseases. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) from 2012 to today and reference lists of respective articles. Only articles published in English language were included. Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.